{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:41:02Z","timestamp":1781840462646,"version":"3.54.5"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objective<\/jats:title><jats:p>The primary objective of this retrospective safety study was to determine the incidence of torsades de pointes (TdP) or death following perioperative administration of low\u2010dose, 4\u00a0mg, ondansetron for postoperative nausea and vomiting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Setting<\/jats:title><jats:p>This is a single\u2010center retrospective clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>The authors identified 32,737 patients who received 37,589 doses of ondansetron during a 2\u2010year time frame between March 2009 and February 2011 for surgical nausea prophylaxis or treatment of nausea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>Patients were cross\u2010matched with an electrocardiogram and adverse outcome database; this identified 4759 patients with documentation of a QTc &gt;450\u00a0milliseconds (ms), all ventricular tachycardias including TdP within 48\u00a0hours of receiving ondansetron, or death within 7\u00a0days of receiving ondansetron. No patients developed TdP or died as a direct result of ondansetron administration (<jats:italic>n<\/jats:italic>\u00a0=\u00a00; event rate\u00a0=\u00a00.0 per 10,000, 95% CI 0.0 to 1.1 per 10,000). Forty\u2010six of 32,737\u00a0surgical patients had documented monomorphic ventricular tachycardia (VT) (<jats:italic>n<\/jats:italic> = 14; event rate = 4.3 per 10,000, 95% CI 2.3 to 7.2 per 10,000) or died (<jats:italic>n<\/jats:italic> = 32; event rate = 9.8 per 10,000, 95% CI 6.7 to 13.8 per 10,000) within 48\u00a0h of ondansetron administration. All monomorphic VT episodes were precipitated by existing cardiovascular disease; and 7 of 14 patients had documented monomorphic VT prior to receiving ondansetron. Of the 32 surgical patients who died, all deaths were precipitated by pre\u2010existing disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No episodes of TdP were identified in patients receiving ondansetron perioperatively. This suggests that low\u2010dose ondansetron does not contribute to the development of TdP.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2668","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T12:18:04Z","timestamp":1644149884000},"page":"292-297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The incidence of torsades de pointes with peri\u2010operative low\u2010dose ondansetron administration"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-4094","authenticated-orcid":false,"given":"Gregory A.","family":"Nuttall","sequence":"first","affiliation":[{"name":"Department of Anesthesiology Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Voogd","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Danke","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Warner","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance J.","family":"Oyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Shirk","family":"Marienau","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Nurse Anesthesia Program Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics and Pharmacology Mayo Clinic College of Medicine  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181ea7821"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000002"},{"key":"e_1_2_7_4_1","unstructured":"U.S. Food and Drug Administration.FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran).https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010new\u2010information\u2010regarding\u2010qt\u2010prolongation\u2010ondansetron\u2010zofran. Accessed November 12 2017."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2013.10.026"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-010-9288-2"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e328338c9f7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31827dde8d"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200506000-00006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31817fd8c8"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.10.008"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0000000000000757"},{"key":"e_1_2_7_14_1","first-page":"53","article-title":"Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study","volume":"3","author":"Hafermann MJ","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"key":"e_1_2_7_15_1","unstructured":"GSK Clinical Trials Registry.A randomized double\u2010blind four\u2010period crossover study to investigate the effect of intravenous ondansetron a 5\u2010HT3 antagonist on cardiac conduction as compared to placebo and moxifloxacin in healthy adult subjects. Clinical study ID: S3A115458. 2011 September 21."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1100073"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2668","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:13Z","timestamp":1761058993000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/phar.2668"],"URL":"https:\/\/doi.org\/10.1002\/phar.2668","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"2021-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}